13 min
Will the Biotech Rebound Run into Pricing Policy Obstacles? Pathfinders in Biopharma
-
- Investing
Drug pricing is already an issue in the U.S. election campaign. Brian Abrahams, MD and Head of Biotech Research at RBC Capital Markets joins the Pathfinders in Biopharma podcast to consider how this, together with other policy developments in the U.S. and worldwide, might affect a resurgent biotech sector.
Drug pricing is already an issue in the U.S. election campaign. Brian Abrahams, MD and Head of Biotech Research at RBC Capital Markets joins the Pathfinders in Biopharma podcast to consider how this, together with other policy developments in the U.S. and worldwide, might affect a resurgent biotech sector.
13 min
More by RBC
Pathfinders in Biopharma
RBC Capital Markets
Disruptors
RBC Thought Leadership, John Stackhouse
The 10-Minute Take
RBC Thought Leadership
RBC's Markets in Motion
RBC Capital Markets
The Download with David Richardson
RBC Global Asset Management (RBC GAM)
Money Moves: Conversations about Investing
Globe Content Studio / RBC